A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

Issued on behalf of Helus Pharma™

Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., says its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major depressive disorder has surpassed 86% enrollment, keeping the FDA Breakthrough-designated program on track for a topline data readout in Q4 2026.

NEW YORK and TORONTO,June 26, 2026/PRNewswire/ --USA News GroupNews Commentary,In drug development, enrollment is the quiet variable that decides whether a promising therapy ever reaches a data readout on schedule. Late-stage psychiatric trials are notoriously hard to fill, which is why a clean enrollment update is meaningful. On June 24, 2026, Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., reported that its APPROACH Phase 3 trial of HLP003 for the adjunctive treatment of major depressive disorder has surpassed 86% enrollment and is progressing as planned, keeping the program on course for a topline data readout in the fourth quarter of 2026.

• Helus Pharma™(NASDAQ:HELP) (Cboe CA: HELP) reported that itsAPPROACH Phase 3 trialof HLP003 for the adjunctive treatment of major depressive disorder (MDD) hassurpassed 86% enrollmentand is progressing as planned.

• HLP003 has previously been grantedBreakthrough Therapy Designation by the U.S. FDA, and the Company says it remains on track for atopline data readout in Q4 2026.

• Company-reported Phase 2 results showed a~23-point MADRS reductionfrom baseline at 12 months (after two 16 mg doses three weeks apart), with response/remission rates of 75% at week 18 improving to100% response and 71% remissionat 12 months — figures that have not been evaluated by the FDA.

"We are pleased with the continued progress of the APPROACH study as we surpass 86% enrollment," said Eric So, Interim Chief Executive Officer of Helus Pharma. "This milestone underscores the execution of our clinical program and brings us closer to the anticipated topline data readout in the fourth quarter of 2026. We remain focused on advancing HLP003 as a potential transformative treatment option for patients living with MDD."

APPROACH is one of the Company's Phase 3 studies evaluating HLP003, its lead proprietary novel serotonergic agonist (NSA). The trial sits within a broader Phase 3 program Helus calls PARADIGM, which also includes the EMBRACE study and the EXTEND long-term extension study — a multi-trial structure designed to build the efficacy and safety package required to advance HLP003 toward potential commercialization.

Helus describes its proprietary NSAs as synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity — the brain's capacity to form new neural connections — with the aim of delivering durable improvements rather than the symptom-by-symptom maintenance of traditional antidepressants. HLP003 is the lead candidate, now in Phase 3 for the adjunctive treatment of MDD; the Company is also developing HLP004, an NSA in Phase 2 for generalized anxiety disorder, alongside a broader portfolio of investigational NSAs.

The FDA's Breakthrough Therapy Designation, which HLP003 has received, is granted to investigational therapies intended to treat serious conditions where preliminary clinical evidence suggests a substantial improvement over available options. The designation is meant to expedite development and review through more intensive FDA guidance — it is a signal of regulatory engagement and perceived promise, not a guarantee of approval. For a clinical-stage company, it is among the more meaningful validations a program can carry into late-stage trials.

The reason HLP003 has drawn attention is the strength of its earlier-stage results. In previously reported Phase 2 data, the Company says HLP003 demonstrated long-term efficacy with an approximately 23-point reduction in the Montgomery-Asberg Depression Rating Scale (MADRS) score compared to baseline at 12 months, following two 16 mg doses administered three weeks apart. The MADRS is the standard clinician-rated instrument for measuring depression severity, and a reduction of that magnitude, if it holds up in a larger controlled trial, would be clinically substantial.

The Company further reported that Phase 2 response and remission rates were 75% at week 18, and that by the 12-month mark response and remission rates improved to 100% and 71%, respectively. These are striking figures — but important caveats apply, and Helus Pharma itself flags them: Phase 2 studies are typically small and may lack the controls of a pivotal trial, results from a Phase 2 study may not be predictive of Phase 3 outcomes, and the FDA has not evaluated these results or confirmed any efficacy claims for HLP003. The APPROACH Phase 3 trial exists precisely to test whether the early signal can be reproduced rigorously at larger scale.

The opportunity backdrop is significant. Major depressive disorder affects hundreds of millions of people worldwide and remains a leading cause of disability, yet the workhorse treatments — SSRIs and SNRIs — are built on chemistry that is decades old, can take weeks to work, and leave a large share of patients with inadequate relief. That gap is why the depression field is, in the words of one 2026 industry analysis, undergoing its most significant therapeutic transformation in decades, as mechanistically novel drugs reach the market and late-stage pipeline at the same time.

Helus is positioning HLP003 squarely in that opening: a fast-acting, durable, neuroplasticity-oriented option intended to work adjunctively for patients whose depression is not adequately controlled. The thesis is that an adjunctive treatment requiring only periodic dosing could reshape how MDD is managed — if the Phase 3 data deliver. The Company operates across Canada, the United States, the United Kingdom, and Ireland.

A handful of clinical-stage developers are pursuing novel-mechanism therapies for depression using the same pivotal-trial yardstick Helus relies on — the MADRS. Three are worth watching as the most direct points of comparison, though each carries its own risk profile, targets its own patient population, and none is a proxy for Helus.Compass Pathways (NASDAQ:CMPS) is among the most advanced: its synthetic psilocybin candidate, COMP360, is in Phase 3 for treatment-resistant depression, and in early 2026 the company reported achieving the primary endpoint in both of its pivotal Phase 3 trials using the same MADRS-based measurement. It offers the clearest read on how regulators and markets are treating late-stage, novel-mechanism depression programs.

Definium Therapeutics (NASDAQ:DFTX), the company formerly known as Mind Medicine (MindMed) and renamed in January 2026, is an especially timely comparison. In June 2026 it reported positive topline results from its Phase 3 Emerge study of DT120 (lysergide) orally disintegrating tablet in MDD: the study met its primary endpoint with a placebo-adjusted MADRS reduction of 8.1 points at week 6 (p<0.0001) and, the company reported, met all key secondary endpoints, with DT120 generally well tolerated and no serious adverse events. Alongside the data, Definium priced an upsized US$700 million public offering. As a single-dose, novel-mechanism MDD program measured on the MADRS, it is among the most directly relevant readouts for how a program like HLP003 may be received — while also illustrating the competitive intensity Helus faces in the space.

GH Research (NASDAQ:GHRS), a Dublin-based clinical-stage company developing its own novel-mechanism candidate for treatment-resistant depression, rounds out the set as another developer racing to convert an early efficacy signal into pivotal data. It is pre-revenue and carries the binary clinical risk inherent to late-stage biotech. Together, these names illustrate a depression field being remade around new mechanisms — and the distance a clinical-stage company likeHelusmust still travel, through its Q4 2026 readout and beyond, to convert promise into an approved product.

An 86% enrollment milestone is an execution signal, not a result — it says the trial is on track to read out, not what it will show. But for a Breakthrough-designated program with eye-catching Phase 2 data and a Q4 2026 topline readout in sight, hitting enrollment targets on schedule is exactly what de-risks the path to that catalyst. The questions that matter now are whether APPROACH completes enrollment cleanly, whether the Phase 3 data reproduce the Phase 2 results, and how the FDA ultimately views the package. For investors tracking the next generation of depression therapeutics, the Q4 readout is the date to circle — with the clear understanding that HLP003 is investigational, unapproved, and unproven until that data arrives.

Signal over noise. Biotech, neuroscience, and clinical-trial headlines move fast — and the crowd often moves first. Eagle Eye is a real-time investor signal-intelligence platform that surfaces sentiment shifts, news flow, and trending tickers as they happen, so you see the move forming instead of reading about it later. See it ateagle-eye.dev.

[1] Helus Pharma™ (Cybin Inc.), "Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress," June 24, 2026.[2] Compass Pathways plc (Nasdaq:CMPS), Phase 3 COMP005 and COMP006 (COMP360 psilocybin for treatment-resistant depression) primary-endpoint disclosures, 2025–2026.[3] Definium Therapeutics, Inc. (Nasdaq:DFTX), "Positive Topline Results from Phase 3 Emerge Study of DT120 ODT in MDD" and "Pricing of $700 Million Upsized Public Offering," June 2026.[4] GH Research PLC (Nasdaq:GHRS), corporate and clinical-program disclosures, 2026.[5] Depressive-disorder competitive-landscape analysis, 2026.